Lixte Biotechnology Holdings, Inc. (LIXT)

US — Healthcare Sector
Peers: ALLR  NRBO  HILS  VRAX  QNRX  INDP  KTTA  KRBP  BDRX  PMVP  OLMA  ENOB  SRRK  PASG 

Automate Your Wheel Strategy on LIXT

With Tiblio's Option Bot, you can configure your own wheel strategy including LIXT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LIXT
  • Rev/Share 0.0
  • Book/Share 0.469
  • PB 2.4947
  • Debt/Equity 0.0
  • CurrentRatio 3.8995
  • ROIC -4.1535

 

  • MktCap 3140362.0
  • FreeCF/Share -1.1911
  • PFCF -1.0668
  • PE -0.8699
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -2.3747

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
LIXT
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral

PASADENA, CALIF., Feb. 11, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 434,784 shares of its common stock at a purchase price of $2.415 per share, in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to an aggregate of 434,784 shares of common stock. The warrants will have an exercise price of …

Read More
image for news LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement
LIXT
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the “SEC”) of the Company's Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the “Registration Statement”), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been …

Read More
image for news LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

About Lixte Biotechnology Holdings, Inc. (LIXT)

  • IPO Date 2007-10-25
  • Website https://lixte.com
  • Industry Biotechnology
  • CEO Mr. Bastiaan van der Baan M.Sc.
  • Employees 2
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.